Biological and therapeutic challenges
著者
書誌事項
Biological and therapeutic challenges
(Ovarian cancer, [1])
Chapman and Hall Medical, 1990
大学図書館所蔵 全8件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Based on the proceedings of the Second Helene Harris Memorial Trust Biennial International Furum on Ovarian Cancer, held in Graz, Austria
内容説明・目次
内容説明
This volume presents the current aspects of molecular biology, genetics, screening, chemotherapy and surgery, as they relate to ovarian cancer. Scientists and clinicians from major international research and treatment centres have contributed a wealth of material on current scientific developments and management trends. This book should be of interest to medical oncologists, gynaecologists, molecular biologists, pathologists and surgeons.
目次
- Part 1 Genetic aspects
- risk of ovarian cancer associated with a family history - preliminary report of the OPCS study, Bruce Ponder
- hereditary ovarian cancer, Henry T. Lynch
- genetic perspective in ovarian cancer, Stig Kullander
- discussion, Bruce Ponder. Part 2 Biological aspects: ovarian cancer biology - progress and problems, Sir Walter Bodmer
- animal models of ovarian cancer, Frances Balkwill
- discussion
- new approaches in breast cancer research, Ruth Sager
- discussion
- regulatory mechanisms in ascitic fluid, Gordon Mills
- the role of oncogenes in ovarian cancer, William Guillick
- the prognostic value of steroid receptors, growth factors and growth receptor factors in ovarian cancer, Robin Leake
- discussion. Part 3 Biological aspects: immunological control of ovarian cancer, Jonathan Berek
- discussion
- MHC expressions on tumour cells, Hilliard Festenstein
- discussion
- agNOR counts in borderline ovarian tumours, Wayne Kinsey
- discussion
- flow cytometric quantitation of p62 and DNA in serious papillary ovarian cancer, James Watson
- drug resistance analysis in populations of individual cells using flow cytometry, James Watson
- ras oncogene expression in advanced ovarian cancer
- discussion
- the pathology of early malignant change, Harold Fox
- intraperitoneal and retroperitoneal spread of ovarian cancer, Helmut Pickel
- discussion. Part 4 Early detection and screening: does ovarian adenocarcinoma arise from pre-existing benign cysts?
- the case against, Harold Fox
- malignant potential of benign ovarian cysts
- the case for, Malcolm Anderson
- Malcolm Anderson
- discussion
- potential screening tests for ovarian cancer, Ian Jacobs
- discussion
- tumour markers and the adnexal mass, Bill Creasman
- discussion
- developments in ultrasound screening for early ovarian cancer, Stuart Campbell
- the evaluation of screening tests for ovarian cancer, Howard Cuckle
- population-based studies of ovarian cancer screening - one way ahead?, Frank Sharp
- discussion
- the value of a combination of tumour markers in ovarian cancer, Manfred Lahousen
- potential future screening markers, Robert Bast
- discussion. Part 5 Update on potential advances in therapy: dose intensity considerations in chemotherapy, Leslie Levin
- single versus multiple agent regimes, Bill Creasman
- the place for single agent chemotherapy, Stan Kaye
- discussion
- high-dose chemotherapy and autologous bone marrow transplantation in epithelial ovarian cancer, Frank G. Lawton
- care of the patient with ovarian cancer - a quality of life perspective, Denny DePetrillo
- intraperitoneal therapy in ovarian cancer, George Blackledge
- (Partial contents)
「Nielsen BookData」 より